Compare Illumina, Inc. (ILMN) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Centrus Energy Corp — how do they compare? Illumina, Inc. trades at $191.47 (market cap $29.12B), while Centrus Energy Corp trades at $185.89 (market cap $3.77B). The key difference: Illumina, Inc. is far larger — about 7.7× Centrus Energy Corp's market cap, and Illumina, Inc. is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| ILMN | LEU | |
|---|---|---|
Market Cap | $29.12B | $3.77B |
Sector | Health | Energy |
52-Week High | $205.10 | $436.00 |
52-Week Low | $91.00 | $146.61 |
Enterprise Value | $30.48B | $3.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
Centrus Energy (LEU) trades at $186.93, down 1.27% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, beating earnings estimates but showing margin compression. LEU maintains a strong $4.5 billion backlog and secured significant DOE funding, positioning it as a key player in the domestic nuclear fuel supply chain. Valuation metrics appear elevated with a P/E of 68.23 and P/S of 8.89, reflecting growth expectations in the nuclear energy sector.
The outlook remains positive given government support for nuclear energy and Centrus's strategic position in HALEU production. However, investors face risks from execution challenges, cost pressures, and the capital-intensive nature of enrichment facility expansion. Analyst consensus leans bullish with a $228.50 price target, though the stock's premium valuation requires careful monitoring of operational milestones and margin trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
